Leidi.com Lei Jianping July 21
Jiangxi Shimei Pharmaceutical Co., Ltd. (abbreviation: "Shimei Pharmaceutical") recently submitted a prospectus, preparing to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market.
Shimei Pharmaceutical plans to raise 608 million yuan, of which 245 million yuan will be used for chiral antihypertensive drug research and development and industrialization construction projects, 230 million yuan will be used for Shandong innovative drug research and development and preparation production base construction projects, and 132 million yuan will be used for Shandong Kexin API production base construction projects.
Annual revenue 184 million
Shimei Pharmaceutical is an innovative pharmaceutical company with research and development as the core driving force. It focuses on the research and development, production and sales of generic drugs, improved innovative drugs, and innovative drugs.
Shimei Pharmaceutical focuses on the "big disease, big market, big variety" disease fields such as chiral three-high drugs, kidney disease and hemodialysis drugs, psychoneurotic drugs, rare disease and children's drugs, skin and medical beauty drugs, andrology and reproductive health drugs, vitamin and mineral drugs, etc., through the differentiated research and development strategy of "first imitation, rush imitation, high difficulty imitation", and adopts the business model of "independent project establishment, self-development, self-declaration, and opportunistic transfer", forming multi-link and multi-field service and operation capabilities.
Shimei Pharmaceutical is a joint stock limited company established by Shimei Co., Ltd., which was formerly known as Jiangxi Wenzao Pharmaceutical Co., Ltd. Due to poor management and serious losses, in February 2006, Wenzao Pharmaceutical's shareholder meeting resolved that all shareholders would sell 100% of Wenzao Pharmaceutical's equity to the outside world. As of April 2006, Jianghong and Jiang Yangqi, the equity transferees, had paid a total of 3.8625 million yuan for the equity transfer to all 314 shareholders who actually contributed capital to Wenzao Pharmaceutical.
According to the prospectus, the revenue of Shimei Pharmaceutical in 2020, 2021, and 2022 will be 81.395 million yuan, 148 million yuan, and 184 million yuan respectively; the net profit will be 19.31 million yuan, 51.5365 million yuan, and 75.583 million yuan;
Jiang Hong controls 71.2% of the shares
As of the signing date of this prospectus, Jiang Hong directly holds 57.562 million shares of the company, accounting for 54.82% of the company's total shares. At the same time, Jiang Hong, as the executive partner of Honghui Investment, holds 86% of Honghui Investment's property shares, thus indirectly holding 16.38% of the company's shares.
To sum up, Jiang Hong directly and indirectly holds 71.2% of the company's equity, and serves as the company's chairman and general manager. Therefore, Jiang Hong is the controlling shareholder and actual controller of the issuer.
Before the IPO, Honghui Investment held 19.05%, Hongkang Investment held 18.94%, China Medical System Ventures held 4.76%, Liu Yongqiang held 0.73%, Suzhou Ruihe Dinghui Investment Management Partnership (Limited Partnership) held 0.38%, Zhang Haiying held 0.33%, Lei Jincheng held 0.29%, Yuan Hong held 0.19%, and Chen Xianwei held 0.11% %.
Jiang Yangqi, a limited partner of Honghui Investment, subscribed for 10% of the capital, and Jiang Hong is a brother; Jiang Huan, a limited partner of Honghui Investment, subscribed for 0.58% of the capital, and Jiang Tong subscribed for 0.5%. Jiang Wuqi, the father of Jiang Huan and Jiang Tong, and Jiang Hong are both brothers;
Jiang Yangqi is a director of Shimei Pharmaceutical and serves as an executive partner in Hongkang Investment. He holds 90% of Hongkang Investment's shares and has a brotherly relationship with Jiang Hong.
Wei Manyu, partner of Suzhou Ruihe Dinghui Investment Management Partnership (Limited Partnership), and Wei Man, another partner of Suzhou Ruihe, are sisters.
After the IPO, Jianghong held 41.12%, Honghui Investment held 14.29%, Hongkang Investment held 14.21%, China Medical System Ventures held 3.57%, Liu Yongqiang held 0.55%, Suzhou Ruihe Dinghui Investment Management Partnership (Limited Partnership) held 0.29%, Zhang Haiying held 0.25%, Lei Jincheng held 0.21%, and Yuan Hong held 0.14% %, Chen Xianwei holds 0.08%.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
